This company has been marked as potentially delisted and may not be actively trading. Seneca Biopharma (SNCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SNCA vs. IZTC, CRTX, CVM, ZIVO, JATT, CLDI, FNCH, ALVR, CHRO, and NKGNShould you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include Invizyne Technologies (IZTC), Cortexyme (CRTX), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), JATT Acquisition (JATT), Calidi Biotherapeutics (CLDI), Finch Therapeutics Group (FNCH), AlloVir (ALVR), Chromocell Therapeutics (CHRO), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector. Seneca Biopharma vs. Its Competitors Invizyne Technologies Cortexyme CEL-SCI ZIVO Bioscience JATT Acquisition Calidi Biotherapeutics Finch Therapeutics Group AlloVir Chromocell Therapeutics NKGen Biotech Invizyne Technologies (NASDAQ:IZTC) and Seneca Biopharma (NASDAQ:SNCA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk. Do institutionals and insiders believe in IZTC or SNCA? 5.2% of Seneca Biopharma shares are owned by institutional investors. 2.1% of Seneca Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer IZTC or SNCA? In the previous week, Invizyne Technologies' average media sentiment score of 0.00 equaled Seneca Biopharma'saverage media sentiment score. Company Overall Sentiment Invizyne Technologies Neutral Seneca Biopharma Neutral Which has better earnings & valuation, IZTC or SNCA? Invizyne Technologies has higher earnings, but lower revenue than Seneca Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/ASeneca Biopharma$10K1,366.56-$8.35MN/AN/A Is IZTC or SNCA more profitable? Invizyne Technologies has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. Invizyne Technologies' return on equity of 0.00% beat Seneca Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Seneca Biopharma -230.34%-122.20%-110.61% SummaryInvizyne Technologies and Seneca Biopharma tied by winning 3 of the 6 factors compared between the two stocks. Get Seneca Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNCA vs. The Competition Export to ExcelMetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.67M$281.95M$5.44B$9.61BDividend YieldN/AN/A4.61%4.14%P/E RatioN/AN/A29.7524.84Price / Sales1,366.56462.25449.1298.65Price / CashN/A22.4436.4258.36Price / Book0.598.908.185.64Net Income-$8.35M-$115.81M$3.26B$265.68M Seneca Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNCASeneca BiopharmaN/A$0.79-10.1%N/A-75.9%$13.67M$10K0.007Gap DownIZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpCRTXCortexymeN/A$1.85-0.5%N/A+142.0%$55.78MN/A-0.6255CVMCEL-SCI0.9979 of 5 stars$8.58+20.0%N/A-79.5%$45.65MN/A-17.8743High Trading VolumeZIVOZIVO BioscienceN/A$10.70flatN/A+75.6%$40.84M$15.85K-2.1910Upcoming EarningsGap DownHigh Trading VolumeJATTJATT AcquisitionN/A$1.47-9.3%N/A-58.1%$25.36MN/A0.003High Trading VolumeCLDICalidi Biotherapeutics0.168 of 5 stars$0.59-7.4%N/A-75.1%$21.25MN/A0.0038Negative NewsFNCHFinch Therapeutics GroupN/A$12.50flatN/A+197.7%$20.08MN/A-1.42190Gap DownALVRAlloVirN/A$2.69-8.0%N/A-84.0%$13.57MN/A-0.13110High Trading VolumeCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-80.4%$8.69MN/A-1.084Gap UpHigh Trading VolumeNKGNNKGen Biotech0.4865 of 5 stars$0.14-26.3%N/A-86.3%$6.29MN/A-0.03N/AShort Interest ↑Gap Down Related Companies and Tools Related Companies Invizyne Technologies Alternatives Cortexyme Alternatives CEL-SCI Alternatives ZIVO Bioscience Alternatives JATT Acquisition Alternatives Calidi Biotherapeutics Alternatives Finch Therapeutics Group Alternatives AlloVir Alternatives Chromocell Therapeutics Alternatives NKGen Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNCA) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
